跳转至内容
Merck
  • Prototype of biliary drug-eluting stent with photodynamic and chemotherapy using electrospinning.

Prototype of biliary drug-eluting stent with photodynamic and chemotherapy using electrospinning.

Biomedical engineering online (2014-08-21)
Min-Hua Chen, Po-Chin Liang, Kai-Chun Chang, Jian-Yuan Huang, Yu-Ting Chang, Fuh-Yu Chang, Jau-Min Wong, Feng-Huei Lin
摘要

The combination of biliary stent with photodynamic and chemotherapy seemed to be a beneficial palliative treatment of unresectable cholangiocarcinoma. However, by intravenous delivery to the target tumor the distribution of the drug had its limitations and caused serious side effect on non-target organs. Therefore, in this study, we are going to develop a localized eluting stent, named PDT-chemo stent, covered with gemcitabine (GEM) and hematoporphyrin (HP). The prototype of PDT-chemo stent was made through electrospinning and electrospraying dual-processes with an electrical charge to cover the stent with a drug-storing membrane from polymer liquid. The design of prototype used PU as the material of the backing layer, and PCL/PEG blends in different molar ratio of 9:1 and of 1:4 were used in two drug-storing layers with GEM and HP loaded respectively. The optical microscopy revealed that the backing layer was formed in fine fibers from electrospinning, while drug-storing layers, attributed to the droplets from electrospraying process. The covered membrane, the morphology of which was observed by scanning electron microscopy (SEM), covered the stent surface homogeneously without crack appearances. The GEM had almost 100% of electrosprayed efficiency than 70% HP loaded on the covered membrane due to the different solubility of drug in PEG/PCL blends. Drug release study confirmed the two-phased drug release pattern by regulating in different molar ratio of PEG/PCL blends polymer. The result proves that the PDT-chemo stent is composed of a first burst-releasing phase from HP and a later slow-releasing phase from GEM eluting. This two-phase of drug eluting stent may provide a new prospect of localized and controlled release treatment for cholangiocarcinoma disease.

材料
货号
品牌
产品描述

Sigma-Aldrich
四氢呋喃, inhibitor-free, suitable for HPLC, ≥99.9%
Sigma-Aldrich
四氢呋喃, contains 250 ppm BHT as inhibitor, ACS reagent, ≥99.0%
Sigma-Aldrich
1,1,1,3,3,3-六氟-2-丙醇, ≥99%
Sigma-Aldrich
四氢呋喃, anhydrous, ≥99.9%, inhibitor-free
Sigma-Aldrich
四氢呋喃, anhydrous, contains 250 ppm BHT as inhibitor, ≥99.9%
Sigma-Aldrich
四氢呋喃, ReagentPlus®, ≥99.0%, contains 250 ppm BHT as inhibitor
Sigma-Aldrich
四氢呋喃, contains 250 ppm BHT as inhibitor, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.9%
Sigma-Aldrich
L-赖氨酸 单盐酸盐, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
四氢呋喃, ACS reagent, ≥99.0%, contains 250 ppm BHT as inhibitor
Supelco
1,1,1,3,3,3-六氟-2-丙醇, for GC derivatization, LiChropur, ≥99.8%
Sigma-Aldrich
L-赖氨酸 单盐酸盐, reagent grade, ≥98% (HPLC)
Supelco
四氢呋喃, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
四氢呋喃, analytical standard
Supelco
四氢呋喃, Selectophore, ≥99.5%
Supelco
L-赖氨酸 单盐酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-赖氨酸 单盐酸盐, BioUltra, ≥99.5% (AT)
赖氨酸 盐酸盐, European Pharmacopoeia (EP) Reference Standard
Supelco
L-赖氨酸盐酸盐 溶液, 100 mM amino acid in 0.1 M HCl, analytical standard
Supelco
L-赖氨酸 单盐酸盐, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland